Kaken Pharmaceutical (TYO:4521) revised its consolidated earnings forecast for the fiscal year ending March 31, raising net sales outlook to 94 billion yen due to an upfront payment from a licensing deal for its STAT6 inhibitor.

Net profit was slightly adjusted downward to 14 billion yen, reflecting expenses from a recent dermatology licensing agreement and the acquisition of Aadi Subsidiaries, according to its Tuesday bourse filing.

The revision follows deals disclosed in December 2024 and March 2025, including a collaboration with Alumis for ESK-001 in Japan and the completion of Aadi's acquisition.

Despite the adjustments, Kaken's projected earnings still show significant growth compared with the previous fiscal year, with net sales up 30.5% and operating profit more than doubling.

Shares of the company dropped over 5% in morning trade Wednesday.

Price (JPY): $4236.00, Change: $-230, Percent Change: -5.13%